In The News

    • APR 05 2018

    Musella Foundation About ONC201 Clinical Trials in Pediatric and Adult Patients with H3 K27M Glioma

    Brain Tumor News Blast Issue 5,656 (Wednesday, April 4, 2018): ONC201 is an experimental, orally bioavailable, first-in-class small molecule with demonstrated antitumor activity in preclinical models of difficult-to-treat solid and liquid tumors without imparting significant toxicity. It is currently investigated for its safety and efficacy in the following clinical trials: 1) ONC-201 for Recurrent Glioblastomas

    • MAR 29 2018

    OncologyTube: Dr. Chi talks about his ONC201 trial in H3 K27M-mutant gliomas

    In the videos below, Dr. Andrew Chi talks about ONC201 and his Phase II – Adults with Recurrent H3 K27M High-grade Glioma (NCT03295396) at NYU Langone. H3 K27M-mutant gliomas are known to overexpress DRD2, the target that ONC201 utilizes to drive its anti-cancer effects. Andrew S. Chi, MD PhD, Chief of Neuro-Oncology and the Codirector of

    • MAR 21 2018

    Fox Chase Cancer Center Researchers Uncover ONC201 Immune-oncology Effects

    “Immune cell activation in the tumor and inhibition of metastasis with an oral, infrequently administered and well tolerated small molecule provides an attractive treatment option for patients. Immune activation is recognized as an important requirement to achieve durable and complete remissions in conjunction with standard-of-care therapies,” said El-Deiry. “We discovered ONC201 through its ability to

    • JAN 25 2018

    OncologyTube interviewed Dr. Anderson to talk about his ONC201 trial

    In the videos below, Dr. Peter Anderson talks about ONC201 and his Phase II – Neuroendocrine Tumors (NCT03034200) at The Cleveland Clinic. The clinical trial is evaluating ONC201 in patients with neuroendocrine tumors. These tumors are known to overexpress DRD2, the target that ONC201 utilizes to drive its anti-cancer effects. Dr. Peter Anderson is the